Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis

Summary

A retrospective study evaluated the efficacy and safety of first-line camrelizumab combined with chemotherapy (nab-paclitaxel and cisplatin) for advanced oesophageal squamous cell carcinoma (OSCC), compared to PD-1 monotherapy or chemotherapy alone. The study, involving 253 patients, demonstrated that the combination significantly improved progression-free survival (PFS) compared to the other arms. Although objective response and disease control rates did not differ, median overall survival was longest in the combination group (12.0 months). Adverse events were manageable, with higher rates of anemia and neutropenia in the combination group. An elevated neutrophil-to-lymphocyte ratio (NLR) was identified as an independent prognostic biomarker.

Critical appraisal

This retrospective study, effectively a real-world phase II/III comparison, provides evidence for the superior efficacy of a first-line combination of a PD-1 antibody (camrelizumab) and chemotherapy for advanced oesophageal squamous cell carcinoma (OSCC). The combination significantly improved progression-free survival (PFS) compared to monotherapy or chemotherapy alone (all P<0.001), and demonstrated a longer median overall survival (12.0 months vs 6.0 and 9.0 months). Adverse events were manageable, although anemia and neutropenia were more frequent with the combination. The neutrophil-to-lymphocyte ratio (NLR) ≥5 was identified as an independent, readily available prognostic biomarker, which could aid in patient selection and risk stratification. These findings suggest that this combined regimen could become a preferred option in clinical practice for advanced OSCC, potentially justifying a prospective Phase III trial to confirm these benefits. Clinical impact could be seen in the medium term (3-5 years) if these data are validated.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology